Emergency recall of compounded medication formerly known as Wydase
Published by Cal Warriner in Mass Torts, Product DefectThe FDA has emergently taken possession of medication formerly known under the trade name Wydase (hyaluronidase) due to sight threatening reactions in a number of patients.
The medication is used to augment the effects of common anesthetics such as bupivicaine and is suspected to be contaminated. Commonly used by ophthalmologists during eye surgery, the medication has not been commercially available since Wyeth took Wydase off the market in 2001. Widely used, Wydase was thought to have been administered in over 750,000 surgeries between 1999 and its withdrawal in 2001. The medication had become very popular with eye surgeons due to its ability to potentiate the effects of anesthetic medication. Surgeons were outraged following the withdrawal since the drug had become so popular.



